Radiogenomics in brain, breast, and lung cancer: opportunities and challenges.
Radiogenomics in brain, breast, and lung cancer: opportunities and challenges.
复制标题
DOI：
10.1117/1.jmi.8.3.031907
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Kontos D
中科院分区：
文献类型：
--
作者：
Singh A;Chitalia R;Kontos D
放射基因组学领域主要集中于开发用于基因组签名的成像替代物，并整合成像、基因组和分子数据以开发用于表征各种疾病的组合的个性化生物标记物。我们的研究旨在强调放射基因组学在癌症研究中的最新进展和作用，主要集中在实体肿瘤上，大致分为四个部分。第一部分回顾了利用基因表达和分子图谱信息建立放射组学特征的生物学基础的代表性研究。第二部分包括旨在利用放射组学信号非侵入性预测肿瘤分子亚型的研究。第三部分回顾了评估通过结合来自癌症肿瘤的放射和基因组信号编码的互补信息来增强已建立的预后信号的性能的潜力的研究。第四部分包括侧重于确定放射基因组表型的生物学意义的研究。最后，我们讨论了该领域当前的挑战和机遇，如成像设备制造商、监管组织、医疗保健提供者、制药公司、学术机构和医生之间协调的重要性，以有效标准化放射基因组签名的结果，并潜在地利用这些发现来改善癌症患者的精确护理。
The field of radiogenomics largely focuses on developing imaging surrogates for genomic signatures and integrating imaging, genomic, and molecular data to develop combined personalized biomarkers for characterizing various diseases. Our study aims to highlight the current state-of-the-art and the role of radiogenomics in cancer research, focusing mainly on solid tumors, and is broadly divided into four sections. The first section reviews representative studies that establish the biologic basis of radiomic signatures using gene expression and molecular profiling information. The second section includes studies that aim to non-invasively predict molecular subtypes of tumors using radiomic signatures. The third section reviews studies that evaluate the potential to augment the performance of established prognostic signatures by combining complementary information encoded by radiomic and genomic signatures derived from cancer tumors. The fourth section includes studies that focus on ascertaining the biological significance of radiomic phenotypes. We conclude by discussing current challenges and opportunities in the field, such as the importance of coordination between imaging device manufacturers, regulatory organizations, health care providers, pharmaceutical companies, academic institutions, and physicians for the effective standardization of the results from radiogenomic signatures and for the potential use of these findings to improve precision care for cancer patients.